StockNews.AI
TENX
StockNews.AI
167 days

Tenax Therapeutics Announces $25 Million Private Placement

1. Tenax announced a $25M private placement with RTW Investments. 2. The placement includes 378,346 shares and warrants for 3.76M shares. 3. Funds will advance Phase 3 clinical trials and support general expenses. 4. Closing of the placement is expected on March 5, 2025. 5. Tenax will register shares with the SEC within 45 days post-closing.

6m saved
Insight
Article

FAQ

Why Bullish?

The substantial capital infusion indicates positive market confidence, similar to previous funding rounds boosting stock prices.

How important is it?

The funding is significant, enhancing Tenax's capacity for clinical development and operational sustainability.

Why Short Term?

Immediate capital availability should enhance operational capabilities, influencing stock behavior in the near term.

Related Companies

RTWIPFEVRTX
March 05, 2025 08:47 ET  | Source: Tenax Therapeutics, Inc. CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that it has entered into a securities purchase agreement for a private placement financing with RTW Investments, which is expected to result in total gross proceeds of approximately $25 million to the Company, before deducting placement agent fees and other private placement expenses. The private placement will be for an aggregate of 378,346 shares of the Company’s common stock and pre-funded warrants to purchase an aggregate of 3,760,726 shares of common stock. The purchase price for each share of common stock is $6.04 (provided, the purchase price for each pre-funded warrant is $6.03, with the pre-funded warrants having an exercise price of $0.01). The pre-funded warrants are exercisable at any time after their original issuance and will not expire. The private placement is expected to close on March 5, 2025, subject to the satisfaction of customary closing conditions. Leerink Partners is acting as the lead placement agent for the private placement and is joined by Guggenheim Securities and William Blair as joint placement agents. The Company intends to use the net proceeds from the private placement to advance the Company’s ongoing and planned Phase 3 clinical trials, as well as for working capital, capital expenditures, and other general corporate purposes. The securities to be issued in connection with the private placement described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and have not been registered under the Securities Act, or any state or other applicable jurisdictions’ securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Tenax Therapeutics has agreed to file a registration statement with the United States Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon the exercise of the pre-funded warrants issued in the private placement, no later than 45 days after the closing of the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offering of the securities under the resale registration statement will only be made by means of a prospectus. Caution Regarding Forward-Looking StatementsExcept for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. These forward-looking statements may include information concerning possible or projected future business operations. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: risks associated with market conditions and the satisfaction of closing conditions related to the private placement; the use of proceeds from this private placement and the Company’s existing cash and cash equivalents, the Company’s cash runway with the net proceeds from this offering, and risks associated with the Company’s cash needs; and risks and uncertainties associated with the Company’s business and finances in general; and other risks and uncertainties set forth from time to time in the Company’s SEC filings. Tenax Therapeutics assumes no obligation and does not intend to update these forward-looking statements except as required by law. Contact: Investor and Media: Merrill BarrettArgot Partnerstenax@argotpartners.com

Related News